Systemic Immune Dysregulation Correlates With Clinical Features of Early Non-Small Cell Lung Cancer

Abstract

BackgroundSystemic immune dysregulation correlates with cancer progression. However, the clinical implications of systemic immune dysregulation in early non-small cell lung cancer (NSCLC) remain unclear.MethodsUsing a panel of 9 markers to identify 12 parameters in the peripheral blood of 326 patients (34 in the discovery group and 292 in the validation group), we investigated systemic immune dysregulation in early NSCLC. Then, we analyzed the impact of surgery on the systemic immune state of these patients. Finally, we analyzed correlations between systemic immune dysregulation and the clinical features of early NSCLC.ResultsWe found striking systemic immune dysregulation in the peripheral blood of early NSCLC patients. This dysregulation was characterized by a significant decrease in total lymphocytes, T cells, quiescent T cells, CD4+ T cells, and NKT cells. We also observed increased proportions of activated lymphocytes and activated T cells. Systemic immune dysregulation was increased after surgery. Furthermore, systemic immune dysregulation was correlated with multiple clinical features, such as sex, age, smoking history, pathological type, tumor stage, surgical approach, tumor differentiation, and epidermal growth factor receptor (EGFR) mutation. Finally, we observed that systemic immune dysregulation was correlated with complications and systemic inflammatory response syndrome (SIRS) in early NSCLC patients.ConclusionsOur results reveal systemic immune dysregulation occurring in early NSCLC and demonstrate the correlation between these dysregulations and clinical features. Our findings suggest that systemic immune dysregulation is involved in cancer development and may be a promising candidate for high-risk screening and treatment strategies for early NSCLC.

Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules

“…Advanced solid malignancies are associated with generalized systemic immunosuppression ( 1 ) that may predispose not only for tumor progression and spread, but also for the development of serious microbial and viral infections ( 2 – 4 ). Notably, however, the existence of cancer-related systemic immunosuppression, seemingly from a much earlier stage in the process of tumorigenesis than was previously believed, has recently been convincingly demonstrated both in murine models of experimental tumorigenesis ( 5 , 6 ) and in a number of clinical studies, mostly focused on dendritic cell (DC) dysfunction in various types of cancer ( 1 , 7 – 13 ). In the former context, the preclinical study reported by Allen et al ( 6 ) is particularly noteworthy.…”

Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study

“…Systemic immune dysregulation and cytotoxic agents induced hematopoietic damage together leading to lower peripheral lymphocytes in cancer patients [ 35 ], and people assume that low peripheral lymphocyte counts positively correlate with fewer tumor-infiltrating immunocytes and predict poor responses / outcomes [ 36 ]. Wang et al reported that total lymphocyte count was higher in the ICB benefit group [ 37 ].…”

Molecular subtypes based on metabolic genes are potential biomarkers for predicting prognosis and immune responses of clear cell renal cell carcinoma

“…Based on our results, we could find in general that the MC2 subtype was strongly associated with the shortest OS and the highest stage of ccRCC. This might be due to the immune dysregulation [22][23][24] resulting in the MC2 subtype being less abundant in immune features such as tumor-infiltrating immune cells levels, TME, immune checkpoint molecules, chemokine/chemokine receptor, IFN score, immune cytolytic activity (CYT) score, angiogenesis score. Moreover, the MC2 subtype would benefit from immunotherapy based on the TIDE algorithm.…”